Reprieve Cardiovascular Overview
- Year Founded
-
2018
- Status
-
Private
- Employees
-
28
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$61M
- Investors
-
11
Reprieve Cardiovascular General Information
Description
Developer of an intelligent decongestion management technology designed to advance heart failure treatment. The company uses real-time physiological monitoring, automated therapy recommendations, precise diuretic administration, intelligent decongestion management, personalized fluid management, and integrated clinical workflows, enabling physicians to safely accelerate fluid removal for heart failure patients.
Contact Information
Website
www.reprievecardio.comCorporate Office
- 459 Fortune Boulevard
- Milford, MA 01757
- United States
Corporate Office
- 459 Fortune Boulevard
- Milford, MA 01757
- United States
Reprieve Cardiovascular Timeline
Reprieve Cardiovascular Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 3. Later Stage VC (Series B) | 17-Sep-2025 | $61M | Completed | Clinical Trials - Phase 2 | ||
| 2. Later Stage VC (Series A1) | 17-Nov-2023 | Completed | Clinical Trials - Phase 2 | |||
| 1. Early Stage VC (Series A) | 07-Jun-2022 | $30M | $30M | Completed | Clinical Trials - Phase 1 |
Reprieve Cardiovascular Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B-3 | ||||||||
| Series B-2 | ||||||||
| Series B-1 | ||||||||
| Series A-1 | 12,050,001 | $0.000010 | $1 | $1 | 1x | $1 | 7.44% | |
| Series A | 33,310,000 | $0.000010 | $1 | $1 | 1x | $1 | 20.57% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Reprieve Cardiovascular Comparisons
Industry
Financing
Details
Reprieve Cardiovascular Competitors (14)
One of Reprieve Cardiovascular’s 14 competitors is DexCom, a Formerly VC-backed company based in San Diego, CA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| DexCom | Formerly VC-backed | San Diego, CA | ||||
| Sensible Medical | Venture Capital-Backed | Raleigh, NC | ||||
| Cardiac Dimensions | Venture Capital-Backed | Kirkland, WA | ||||
| Spine Wave | Venture Capital-Backed | Shelton, CT | ||||
| BrioHealth Solutions | Venture Capital-Backed | Suzhou, China |
Reprieve Cardiovascular Patents
Reprieve Cardiovascular Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026128850-A1 | Improved fluid therapy systems, and associated devices and methods | Pending | 12-Dec-2024 | ||
| US-12582773-B2 | Urine output sensing without use of an indwelling catheter, and associated systems, devices, and methods | Active | 16-Feb-2024 | ||
| US-20250262380-A1 | Urine output sensing without use of an indwelling catheter, and associated systems, devices, and methods | Active | 16-Feb-2024 | ||
| WO-2025175244-A1 | Urine output sensing without use of an indwelling catheter, and associated systems, devices, and methods | Pending | 16-Feb-2024 | ||
| US-12471842-B2 | Fluid therapy based on adjusted urine output rate, and associated systems, devices, and methods | Active | 12-Sep-2023 | A61B5/4839 |
Reprieve Cardiovascular Signals
Reprieve Cardiovascular Investors (11)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cadence Capital | Corporation | Minority | ||
| Genesis Capital (Investment Banks) | Investment Bank | Minority | ||
| Santen Ventures | Corporate Venture Capital | Minority | ||
| UNC Health Ventures | Corporate Venture Capital | Minority | ||
| Abiomed | Corporation | Minority |
Reprieve Cardiovascular FAQs
-
When was Reprieve Cardiovascular founded?
Reprieve Cardiovascular was founded in 2018.
-
Where is Reprieve Cardiovascular headquartered?
Reprieve Cardiovascular is headquartered in Milford, MA.
-
What is the size of Reprieve Cardiovascular?
Reprieve Cardiovascular has 28 total employees.
-
What industry is Reprieve Cardiovascular in?
Reprieve Cardiovascular’s primary industry is Biotechnology.
-
Is Reprieve Cardiovascular a private or public company?
Reprieve Cardiovascular is a Private company.
-
What is the current valuation of Reprieve Cardiovascular?
The current valuation of Reprieve Cardiovascular is .
-
What is Reprieve Cardiovascular’s current revenue?
The current revenue for Reprieve Cardiovascular is .
-
How much funding has Reprieve Cardiovascular raised over time?
Reprieve Cardiovascular has raised $103M.
-
Who are Reprieve Cardiovascular’s investors?
Cadence Capital, Genesis Capital (Investment Banks), Santen Ventures, UNC Health Ventures, and Abiomed are 5 of 11 investors who have invested in Reprieve Cardiovascular.
-
Who are Reprieve Cardiovascular’s competitors?
DexCom, Sensible Medical, Cardiac Dimensions, Spine Wave, and BrioHealth Solutions are some of the 14 competitors of Reprieve Cardiovascular.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process